Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ivermectin in dermatology.

Pascal del Giudice1, Olivier Chosidow, Eric Caumes

  • 1Unité Infectiologie-Dermatologie, Hôpital Bonnet 83600, Fréjus, France. del-giudice-p@chi-frejus-saint-raphael.fr

Journal of Drugs in Dermatology : JDD
|July 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrent Facial Folliculitis Caused by Klebsiella aerogenes Sequence Type 117 in Men who Have Sex with Men.

Emerging infectious diseases·2026
Same author

Head and neck manifestations associated with hidradenitis suppurativa: A retrospective multicentre study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies.

The New England journal of medicine·2026
Same author

Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trial.

The British journal of dermatology·2026
Same author

Balanoposthitis due to Klebsiella aerogenes in men who have sex with men.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicentre, assessor blinded, cluster randomised clinical trial.

BMJ (Clinical research ed.)·2026
Same journal

Pigmented Basal Cell Carcinoma in Skin of Color: A Systematic Review of the Literature.

Journal of drugs in dermatology : JDD·2026
Same journal

Latin America Cutaneous Oncology Management (LACOM) II: A Practical Algorithm for Managing Skin Toxicities in Oncology Patients.

Journal of drugs in dermatology : JDD·2026
Same journal

Efficacy and Tolerability of a Topical Pigment-Correcting Serum in Melasma and Postinflammatory Hyperpigmentation.

Journal of drugs in dermatology : JDD·2026
Same journal

Decoding Sensitive Skin Syndrome: International Expert Advisory Insights on Management From India and the United States of America.

Journal of drugs in dermatology : JDD·2026
Same journal

Evaluating the Safety and Efficacy of Sirolimus Topical Gel 0.2% to Treat Acanthosis Nigricans.

Journal of drugs in dermatology : JDD·2026
Same journal

Moringa-Derived Formulations for Hair Growth, Hair Preservation, and Hair Loss: A Systematic Review.

Journal of drugs in dermatology : JDD·2026
See all related articles

Ivermectin is an effective antiparasitic drug for treating various skin conditions like filariasis, strongyloidiasis, cutaneous larva migrans, scabies, and head lice. Its broad-spectrum activity makes it a valuable tool in dermatology and parasitology.

Area of Science:

  • Dermatology
  • Parasitology
  • Pharmacology

Background:

  • Ivermectin, a broad-spectrum antiparasitic, originated in veterinary medicine.
  • It exhibits activity against diverse helminths and arthropods.
  • Recent global reports highlight its efficacy in parasitic diseases with skin involvement.

Purpose of the Study:

  • To review parasitic infections treatable with ivermectin.
  • To focus on conditions with cutaneous tropism.

Main Methods:

  • Literature review of studies on ivermectin treatment.
  • Analysis of case reports and clinical trials.

Main Results:

  • Ivermectin demonstrates efficacy in treating filariasis.

Related Experiment Videos

  • Successful treatment of strongyloidiasis, cutaneous larva migrans, scabies, and head lice confirmed.
  • The drug's utility in treating skin-related parasitic infections is supported by global reports.

    • Conclusions:

    • Ivermectin is a key therapeutic agent for multiple human parasitic skin diseases.
    • Its application in clinical dermatology is well-established.
    • Further research may explore additional applications of ivermectin in treating neglected tropical diseases.